parecoxib has been researched along with Cancer of Esophagus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, CK; He, XH; Huang, HM; Huang, XY; Wu, SP; Zhang, YF | 1 |
| Cebrián, C; Conde, B; Esquivias, P; Esteva, F; Jiménez, P; Lanas, A; Ortego, J; Piazuelo, E; Santander, S | 1 |
2 other study(ies) available for parecoxib and Cancer of Esophagus
| Article | Year |
|---|---|
Parecoxib inhibits esophageal squamous cell carcinoma progression via the PDK1-AKT pathway.
Topics: Animals; Cell Line, Tumor; Cell Movement; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Isoxazoles; Matrix Metalloproteinase 2; Mice; Proto-Oncogene Proteins c-akt | 2022 |
Cyclooxygenase inhibitors decrease the growth and induce regression of human esophageal adenocarcinoma xenografts in nude mice.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Dinoprostone; Esophageal Neoplasms; Female; Gene Expression; Humans; Indomethacin; Isoxazoles; Male; Mice; Mice, Nude; Random Allocation; Receptors, Prostaglandin E; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |